Heron Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Heron Therapeutics Inc.
- Former names
- AP Pharma Inc Advanced Polymer Systems Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- HRTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000818033
- EIN
- 94-2875566
Board of directors
-
Adam Morgan · DirectorSince 2023
-
Barry D. Quart · Director · Chief Executive OfficerSince 2023
-
Craig A. Collard · Director · Chief Executive OfficerSince 2023
-
Craig A. Johnson · DirectorSince 2024
-
Kevin Kotler · DirectorSince 2023
-
Kimberly Manhard · Director · EVP, Drug DevelopmentSince 2023
-
Michael Kaseta · DirectorSince 2024
-
Sharmila Dissanaike · DirectorSince 2024
-
Susan Rodriguez · DirectorSince 2024
-
Thomas Cusack · DirectorSince 2025
-
Waage Christian · DirectorSince 2024
Chief executives
Barry D. Quart
· Chief Executive Officer
Dates unknown
Craig A. Collard
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 6, 2023. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.9%
-
98.0%
-
98.0%
-
98.6%
-
98.7%
-
99.1%
Board connections
3 of this board's directors also sit on 4 other boards.
- via Craig A. Johnson
- via Barry D. Quart
- via Kimberly Manhard
- via Barry D. Quart
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | Hensley Mark Earl Officer (Chief Operating Officer) | Option exercise | +31,250 | — | — |
| Aug 6, 2026 | Hensley Mark Earl Officer (Chief Operating Officer) | Shares withheld for tax | −8,888 | $0.50 | $4,444 |
| Jul 31, 2026 | Hensley Mark Earl Officer (Chief Operating Officer) | Option exercise | +11,769 | — | — |
| Jul 31, 2026 | Craig A. Collard Director, Officer (Chief Executive Officer) | Option exercise | +34,789 | — | — |
| Jul 31, 2026 | Duarte Ira Officer (EVP, Chief Financial Officer) | Option exercise | +11,694 | — | — |
| Jul 31, 2026 | William P. Forbes Officer (EVP, Chief Development Officer) | Option exercise | +11,694 | — | — |
| Jul 31, 2026 | Duarte Ira Officer (EVP, Chief Financial Officer) | Shares withheld for tax | −3,326 | $0.50 | $1,663 |
| Jul 31, 2026 | William P. Forbes Officer (EVP, Chief Development Officer) | Shares withheld for tax | −3,326 | $0.50 | $1,663 |
| Jul 30, 2026 | Craig A. Collard Director, Officer (Chief Executive Officer) | Option exercise | +50,021 | — | — |
| Jul 30, 2026 | Duarte Ira Officer (EVP, Chief Financial Officer) | Option exercise | +13,535 | — | — |
| Jul 30, 2026 | William P. Forbes Officer (EVP, Chief Development Officer) | Option exercise | +11,769 | — | — |
| Jul 30, 2026 | Duarte Ira Officer (EVP, Chief Financial Officer) | Shares withheld for tax | −3,850 | $0.50 | $1,925 |
| Jul 30, 2026 | William P. Forbes Officer (EVP, Chief Development Officer) | Shares withheld for tax | −3,348 | $0.50 | $1,674 |
| Jul 19, 2026 | Craig A. Collard Director, Officer (Chief Executive Officer) | Option exercise | +13,797 | — | — |
| Jul 19, 2026 | Duarte Ira Officer (EVP, Chief Financial Officer) | Option exercise | +3,874 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.